Get the Stockscreener App
2.0846
0.24%
-0.0154
Standard Biotools Inc stock is traded at $2.0846, with a volume of 1.93M.
It is down -0.24% in the last 24 hours and up +13.24% over the past month.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
See More
Previous Close:
$2.10
Open:
$2.08
24h Volume:
1.93M
Relative Volume:
0.99
Market Cap:
$777.57M
Revenue:
$106.34M
Net Income/Loss:
$-74.66M
P/E Ratio:
-1.9666
EPS:
-1.06
Net Cash Flow:
$-46.12M
1W Performance:
+19.71%
1M Performance:
+13.24%
6M Performance:
-16.53%
1Y Performance:
+0.24%
1-Day Range:
$2.06
$2.23
1-Week Range:
$1.72
$2.26
52-Week Range:
$1.21
$3.04
Standard Biotools Inc Stock (LAB) Company Profile
Name
Standard Biotools Inc
Sector
Industry
Phone
(650) 266-6000
Address
2 TOWER PLACE, SOUTH SAN FRANCISCO
Standard Biotools Inc Stock (LAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-12-23 | Initiated | KeyBanc Capital Markets | Overweight |
Standard Biotools Inc Stock (LAB) Latest News
Vanguard Group Inc's Strategic Acquisition in Standard BioTools Inc - GuruFocus.com
Earnings Release: Here's Why Analysts Cut Their Standard BioTools Inc. (NASDAQ:LAB) Price Target To US$3.17 - Yahoo Finance
TD Cowen trims Standard BioTools target, sees upside in margins and SomaScan performance - Investing.com Australia
Standard BioTools Q3 2024 Earnings Preview - MSN
Standard BioTools Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Earnings call: Standard BioTools faces mixed Q3 results amid market challenges - Investing.com Australia
Standard BioTools Inc (LAB) Q3 2024 Earnings Call Highlights: Navigating Market Challenges with ... - Yahoo Finance
Standard BioTools Inc (LAB) Q3 2024 Earnings Call Highlights: Navigating Market Challenges with ... By GuruFocus - Investing.com Canada
Standard BioTools Inc. (NASDAQ:LAB) Q3 2024 Earnings Call Transcript - Insider Monkey
Standard BioTools price target lowered to $2.50 from $2.75 at TD Cowen - TipRanks
Standard BioTools to Participate in Upcoming Investor Conferences - GlobeNewswire
Standard Biotools earnings beat by $0.02, revenue topped estimates - Investing.com Canada
Standard BioTools Inc. Reports Q3 2024 Financial Performance - TipRanks
Standard BioTools: Q3 Earnings Snapshot - mySA
Standard BioTools reports Q3 EPS (7c), consensus (9c) - TipRanks
Standard BioTools (LAB) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Standard BioTools Reports Strong Q3 2024 Performance - TipRanks
Standard BioTools, SomaLogic fall after shareholder nod for merger - MSN
Standard BioTools Reports Third Quarter 2024 Financial Results - GlobeNewswire
Standard BioTools Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Standard BioTools (NASDAQ:LAB) Trading 5.9% HigherShould You Buy? - MarketBeat
Standard BioTools And 2 Other Penny Stocks Executives Are Buying - MSN
Standard BioTools (NASDAQ:LAB) Has Debt But No Earnings; Should You Worry? - Simply Wall St
Standard BioTools (LAB) to Release Earnings on Wednesday - MarketBeat
Millennium Management LLC Acquires Shares in Standard BioTools Inc - Yahoo Finance
Millennium Management LLC Acquires Shares in Standard BioTools I - GuruFocus.com
LABStandard BioTools Inc. Latest Stock News & Market Updates - StockTitan
Standard BioTools Announces Conference Call and Webcast for - GlobeNewswire
Standard BioTools Announces Conference Call and Webcast for Third Quarter 2024 Financial Results on October 30, 2024 - StockTitan
Get in on Standard BioTools Inc’s (LAB) buy-in window today! - SETE News
Financial Analysis: Standard BioTools Inc (LAB)’s Ratios Unveil Key Insights - The Dwinnex
A Guide To The Risks Of Investing In Standard BioTools Inc (LAB) - Knox Daily
Standard BioTools (NASDAQ:LAB) Trading Down 4%Time to Sell? - MarketBeat
Can you now get a good deal on Standard BioTools Inc’s shares? - US Post News
Dimensional Fund Advisors LP Sells 904,474 Shares of Standard BioTools Inc. (NASDAQ:LAB) - MarketBeat
Taking a look at what insiders are doing to gauge the Standard BioTools Inc (LAB)’s direction - Knox Daily
Standard BioTools Inc (LAB) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - The InvestChronicle
Can you still get a good price for Standard BioTools Inc (LAB) Shares at this point? - US Post News
Millennium Management LLC Reduces Holdings in Standard BioTools Inc. (NASDAQ:LAB) - MarketBeat
Understanding the Risks of Investing in Standard BioTools Inc (LAB) - Knox Daily
Standard BioTools Inc (LAB) expanding its growth trajectory ahead - SETE News
19,143 Shares in Standard BioTools Inc. (NASDAQ:LAB) Purchased by Xponance Inc. - Defense World
Renaissance Technologies LLC Has $1.78 Million Position in Standard BioTools Inc. (NASDAQ:LAB) - Defense World
Standard BioTools Inc [LAB] Shares Fall Approximately -31.87% Over the Year - Knox Daily
Is Standard BioTools Inc. (LAB) the Best NASDAQ Stock Under $5? - Insider Monkey
Is Standard BioTools Inc (LAB) a good investment opportunity? - US Post News
Standard BioTools Inc (LAB) receives a Buy rating from TD Cowen - Knox Daily
Standard BioTools Inc (LAB) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Standard BioTools (NASDAQ:LAB) Stock Quotes, Forecast and News Summary - Benzinga
Standard BioTools Inc [LAB] Shares Fall -7.11 % on Wednesday - Knox Daily
Standard BioTools Inc (LAB) Stock: Navigating Drops and Gains - The InvestChronicle
Standard Biotools Inc Stock (LAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.55%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):